AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Let’s understand the company’s strengths and weaknesses to better analyze how to play AbbVie’s stock amid the recent price decrease. ABBV’s Successful New Drugs — Skyrizi and Rinvoq ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and ...